Compare Eli Lilly And Co (LLY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ulta Beauty Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Ulta Beauty Inc trades at $570.37 (market cap $24.12B). The key difference: Eli Lilly And Co is far larger — about 43.1× Ulta Beauty Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Ulta Beauty Inc for 92 Days on average.
| LLY | ULTA | |
|---|---|---|
Market Cap | $1.04T | $24.12B |
Volume | 3,064,878 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $706.82 |
52-Week Low | $799.57 | $450.75 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $1.09T | $26.43B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
ULTA stock trades at $570.37, up 4.56% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The technical outlook is bullish, with the price near resistance at $572, while fundamentals show robust profitability with a 9.34% net margin and 46.12% ROE. Revenue growth is steady, reaching $11.3B in 2025, though margins face slight pressure. Analyst sentiment is positive, with a consensus price target of $624.93 and 59.57% buy ratings.
The stock presents a compelling growth opportunity supported by e-commerce acceleration and expansion into wellness categories, but risks include promotional pressures, flat store traffic, and margin compression. Execution on raised guidance and omnichannel strategy will be critical for sustaining the rally amid competitive and consumer spending headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
